Despite the observed synergy between JAK and BCL-2/BCL-XL inhibition in myeloma it was unclear whether the tumor microenvironment plays a similar role in other malignancies, and whether JAK inhibitors might combine with venetoclax to counteract bone marrow stroma-mediated resistance in those diseases. This evidence concerns the gene BCL2 and neoplasm.